Aquestive Therapeutics (NASDAQ:AQST) Price Target Increased to $13.00 by Analysts at Leerink Partners

Aquestive Therapeutics (NASDAQ:AQST) had its target price hoisted by Leerink Partners from $12.00 to $13.00 in a research report sent to investors on Friday, Benzinga reports. They currently have an outperform rating on the stock.

Several other equities research analysts have also issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday. JMP Securities reissued a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Aquestive Therapeutics presently has an average rating of “Buy” and an average price target of $8.83.

Aquestive Therapeutics Stock Up 0.2 %

Shares of NASDAQ AQST opened at $5.49 on Friday. The stock has a market capitalization of $499.80 million, a PE ratio of -13.07 and a beta of 2.85. The firm has a fifty day moving average of $4.77 and a 200-day moving average of $3.76. Aquestive Therapeutics has a 52-week low of $1.37 and a 52-week high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.08. The firm had revenue of $20.10 million during the quarter, compared to analyst estimates of $12.62 million. During the same period in the prior year, the firm earned ($0.10) earnings per share. Equities research analysts expect that Aquestive Therapeutics will post -0.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC purchased a new position in Aquestive Therapeutics in the first quarter valued at about $1,456,000. Vanguard Group Inc. grew its position in shares of Aquestive Therapeutics by 71.7% during the first quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock worth $13,813,000 after buying an additional 1,353,518 shares in the last quarter. Blue Owl Capital Holdings LP grew its position in shares of Aquestive Therapeutics by 30.3% during the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock worth $2,964,000 after buying an additional 265,000 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Aquestive Therapeutics in the second quarter valued at $594,000. Finally, Lazard Asset Management LLC boosted its stake in Aquestive Therapeutics by 115.5% during the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock valued at $124,000 after acquiring an additional 15,601 shares during the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.